

Advanced Synthesis & Catalysis

Accepted Article

Title: Enzymatic Desymmetrization of 19-nor-Vitamin D3 A-Ring Synthon Precursor: Synthesis, Structure Elucidation, and Biological Activity of 1 α ,25-Dihydroxy-3-epi-19-nor-vitamin D3 and 1 β ,25-Dihydroxy-19-nor-vitamin D3

Authors: Tania González-García, Annemieke Verstuyf, Lieve Verlinden, Susana Fernández, and Miguel Ferrero

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: *Adv. Synth. Catal.* 10.1002/adsc.201800481

Link to VoR: <http://dx.doi.org/10.1002/adsc.201800481>

DOI: 10.1002/adsc.2018((will be filled in by the editorial staff))

Enzymatic Desymmetrization of 19-*nor*-Vitamin D₃ A-Ring Synthon Precursor: Synthesis, Structure Elucidation, and Biological Activity of 1 α ,25-Dihydroxy-3-*epi*-19-*nor*-vitamin D₃ and 1 β ,25-Dihydroxy-19-*nor*-vitamin D₃

Tania González-García,^{a,b} Annemieke Verstuyf,^c Lieve Verlinden,^c Susana Fernández,^{a,*} and Miguel Ferrero^{a,*}

^a Departamento de Química Orgánica e Inorgánica, Universidad de Oviedo, 33006-Oviedo (Asturias), Spain
Fax: (+34)-985-103-446; phone: (+34)-985-102-984 or (+34)-985-105-013; e-mail: fernandezgsusana@uniovi.es or mferrero@uniovi.es

^b Current address: FAES FARMA, 48940-Leioa (Vizcaya), Spain

^c Laboratorium voor Experimentele Geneeskunde en Endocrinologie, Katholieke Universiteit Leuven, Gasthuisberg, B-3000 Leuven, Belgium

Received: ((will be filled in by the editorial staff))

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/adsc.201800481> ((staff))

Abstract. In a search for novel vitamin D derivatives of potential therapeutic value, structurally simple but synthetically challenging A-ring epimers of the 19-*nor*-Calcitriol [19-*nor*-1 α ,25-(OH)₂-D₃] at C1 and C3 were efficiently synthesized. Both analogues (1-*epi*- and 3-*epi*-19-*nor*-Calcitriol) were obtained through a convergent synthesis starting from *cis,cis*-1,3,5-cyclohexanetriol and the protected 25-hydroxy Grundmann's ketone. After Julia-Kocienski coupling of the corresponding C,D-ring/side chain sulfone fragment with the A-ring ketone moiety, both vitamin D analogues were isolated. The critical point was how to determine the structural configuration of both diastereoisomers since similar ¹H NMR spectra were observed. For that, a biocatalytic approach was crucial in the synthesis of orthogonally protected derivatives. NMR spectroscopy allows the unambiguous identification of these compounds and as a result the structural elucidation of the desired vitamin D diastereomeric analogues. Affinity studies demonstrated that these 1,25-19-*nor* analogues have a very low affinity for the vitamin D receptor compared with 1 α ,25-dihydroxyvitamin D₃ or 1 α ,25-dihydroxy-19-*nor*-vitamin D₃. In addition, these analogues have a lower binding affinity for the human vitamin D binding protein than the natural hormone. *In vitro* cell culture studies revealed that synthesized analogues were less active than 1 α ,25-dihydroxyvitamin D₃ in inhibiting cell proliferation.

Keywords: Enzymatic desymmetrization; Vitamin D; 19-*nor* analogues; A-Ring modified analogues; Calcitriol

Introduction

Due to its huge biological importance, 1 α ,25-(OH)₂-D₃ (**2**, Calcitriol, Figure 1), the hormonally active form of vitamin D₃ (**1**), was considered as a candidate for therapeutic usage. However, side effects like

hypercalcemia and hypercalciuria hobble its pharmaceutical interest.^[1]




Figure 1. Vitamin D and 19-*nor*-analogues.

For this reason, research related to vitamin D and especially focused at Calcitriol, has provided synthetic routes and biological activities for over 3,000 new analogues. Nowadays, the emphasis is on obtaining molecules with enhanced molecular activity, as well as reduced calcemic effects.^[2] Simple modifications on the structure of the natural hormone led to interesting analogues. There are several examples where the chirality importance is reflected because of stereoisomers of the same analogue having remarkably different biological profiles. For example, the stereochemistry of C1 and C3 has a strong impact on binding to the vitamin D receptor (VDR) and also to the vitamin D binding protein (DBP). Inversion of the natural orientation of the 3 β -hydroxyl and 1 α -hydroxyl resulted in a 4- to 90-fold reduction in VDR binding. However, inversion of the

1 α -hydroxyl to the 1 β -orientation results in a 65.7-fold increase in DBP binding with respect to 1 α ,25-(OH)₂-D₃, illustrating that the optimal ligand for DBP is 25-OH-D₃. Intriguingly, 1 β ,25-(OH)₂-D₃ was found to be a specific inhibitor of the nongenomic responses of 1 α ,25-(OH)₂-D₃ such as transcaltachia and Ca²⁺ uptake, making it the first analogue that displays antagonist properties at the receptor level.^[3]

It is noteworthy that the removal of the 19-exomethylene function is beneficial in itself. Thus, 1 α ,25-dihydroxy-19-*nor*-vitamin D₃ (**3**) shows minor calcemic effects while retaining good cell-differentiating properties.^[4] In an attempt to carry out the preparation of the corresponding C1 and C3 diastereoisomers of 1 α ,25-(OH)₂-14-*epi*-19-*nor*-D₃ analogues, Wu *et al.*^[5] described the preparation of 1-*epi* and 3-*epi* derivatives of TX522 (**4–6**, Figure 1) through a convergent process whose key step involves the coupling between an aldehyde of A-ring derivative and an allyl bromide CD-ring fragment. The main drawback of this route is the low selectivity obtained in the solvolysis of the coupling reaction product (cyclovitamin intermediate). It proceeds through an intermediate with two rotamers in equilibrium around the 5,6-bond. This disadvantage along with the challenging identification of both isomers has been a barrier to expand the methodology to the synthesis of 1-*epi* or 3-*epi* derivatives of 1 α ,25-(OH)₂-19-*nor*-D₃.

With this goal in mind, here we report a practical approach for the preparation of the synthetically elusive epimers C3 and C1 of 1 α ,25-(OH)₂-19-*nor*-D₃ (**7** and **8**, respectively, Figure 2).





Figure 2. C1 and C3 epimers of 1 α ,25-(OH)₂-19-*nor*-D₃.

Results and Discussion

Chemistry


The convergent construction of the vitamin D skeleton is based on an approach previously reported by Kittaka.^[6] The synthesis of compounds **7** and **8** was envisaged using a Julia-Kociensky olefination to construct the diene unit between the A-ring and the CD-ring/side chain fragment, which was previously reported starting from Grundmann's ketone.^[7] The synthesis of A-ring synthon **11** was developed as shows in Scheme 1. Treatment of *cis,cis*-1,3,5-cyclohexanetriol (**9**) with Et₃N, and *tert*-butyldimethylsilyl chloride (TBDMSCl) at -20 °C led

to the corresponding di-silyl protected derivative **10**, which was next treated with Dess-Martin periodinane reagent to achieve the ketone **11**.



Scheme 1. Preparation of symmetric A-ring synthon **11**. *Reaction conditions:* (a) TBDMSCl, Et₃N, THF, -20 °C, 2 h and then 16 h at r.t. (43%); (b) Dess-Martin reagent, CH₂Cl₂, r.t., 30 min (97%).

Convergent coupling reaction between **11** and the lithium enolate of sulfone **12** (Scheme 2) took place with 51% yield, giving an equimolar diastereomeric mixture, which was hardly separated by HPLC. For this reason, the mixture was treated with tetrabutylammonium fluoride (TBAF), which resulted in silyl ether deprotection, affording the isomers **13** and **14**. These compounds were easily separated by semipreparative HPLC in an equimolar ratio (see Figure S1, Supporting Information).




Scheme 2. Synthesis of 1-*epi* and 3-*epi* 19-*nor*-vitamin D₃ analogues. *Reaction conditions:* (a) LHMDS, THF, -78 °C to -50 °C, 7 h (51%); (b) TBAF, THF, r.t., 2 h (85%); (c) EtOH sat HCl, r.t., 30 min (88% for **7** and 91% for **8**).

Structure determination from conventional techniques was challenging due to the structural similarity of both isomers. Accordingly, an extensive NMR study was performed using a high resolution NMR spectrometer. Despite the fact of using a 600 MHz apparatus, we were not able to distinguish the diastereomers **13** and **14** by NMR methods (see Figure S2, Supporting Information).

To deduce unequivocally the correct stereochemistry of both analogues, our efforts were focused on the design of a new route for the synthesis of an A-ring synthon in which orthogonal protection of hydroxyl groups would be the key to solve the

problem of the structural determination (Scheme 3). For this purpose, we take into account the pioneering work of Wirz and co-workers,^[8] who carried out the acetylation of corresponding mono-TBDMS-protected derivative of **9** catalyzed by QLM lipase to afford the asymmetrically monoacylated compound in quantitative yield and >99% ee. In our case, to facilitate the analysis of the enzymatic reaction by HPLC, we used as silyl ether the TBDPS (UV visible) instead the TBDMS group.



Scheme 3. Preparation of orthogonally protected A-ring synthon **19**. Reaction conditions: (a) TBDPSCI, Et₃N, NaH, THF, 45 °C, 48 h (85%); (b) Lipase, vinyl acetate, solvent, 30 °C; (c) TBDMSCl, Imidazole, CH₂Cl₂, r.t., 3 h (94%); (d) MeONa, MeOH, r.t., 4 h (95%); (e) Dess-Martin reagent, CH₂Cl₂, r.t., 1 h (97%).

Thus, triol **9** was mono-TBDPS-protected by treatment with *tert*-butyldiphenylsilyl chloride (TBDPSCI), Et₃N, and NaH in THF at 40 °C to afford the diol **15** in 85% yield.^[9] At this point, two different easily available lipases were tested for the asymmetric acetylation of *meso*-diol **15** in vinyl acetate: *Candida antarctica* lipase type B (CAL-B, Novozyme 435) and *Pseudomonas cepacia* lipase (PSL-IM). The choice of these enzymes was based on the excellent results that they showed in enzymatic resolution of secondary alcohols via enantioselective acylation or hydrolysis of their esters.^[10]

Table 1. Lipase catalyzed acylation of **15**.^{a)}


Enzyme ^{b)}	Solvent	t (h)	15 (%) ^{b)}	16 (%) ^{b)}	16 ee (%) ^{b)}	20 (%) ^{b)}
1	-	THF	12	>99	-	-
2	-	Toluene	12	>99	-	-
3	-	TBME	12	>99	-	-
4	CAL-B	THF	12	-	92	>99
5	CAL-B	Toluene	12	9	85	98
6	CAL-B	TBME	10	-	90	97
7	PSL-IM	THF	12	74	24	85
8	PSL-IM	Toluene	4	-	>99	>99
9	PSL-IM	TBME	4	-	>99	>99

^{a)} Ratio **15**:enzyme (1:0.5, p/p), with vinyl acetate at 30 °C.

^{b)} Determined by chiral HPLC.

Enzymatic catalysis in non-aqueous media significantly extends the conventional aqueous-based biocatalysis.^[11] The effect of three different organic solvents [THF, *tert*-butylmethyl ether (TBME), and toluene] on the process was evaluated. The reactions were carried out at 30 °C using 5 equiv. of vinyl acetate. *Candida antarctica* lipase B (CAL-B), showed very high enantioselectivity in all solvents (entries 4–6, Table 1) but different regioselectivities: total conversion was achieved with THF and TBME, after 12 and 10 h, respectively, but the diacetylated product **20** was also obtained. Using toluene as solvent, the reaction was slower and after 12 h starting material was recovered.

On the other hand, when the acylation process of **15** was examined with *Pseudomonas cepacia* lipase as catalyst and THF as solvent, lower reaction rate and enantioselectivity were observed (entry 7, Table 1). On the contrary, excellent results were obtained using toluene and TBME (entries 8–9, Table 1). Thus, 99% conversion was achieved after 4 h of reaction and enantiopure (–)-**16** was obtained (see Figure S3, Supporting Information).




Scheme 4. Synthesis of enantiomerically pure diacetate **22**. Reaction conditions: (a) Ph₃P, DIAD, AcOH, THF, r.t., 4 h (72%); (b) TBAF, THF, r.t., 3 h (79%).

Both enzymes showed the same stereochemical preference. For the assignment of the absolute configurations of **16**, a sequence of chemical transformations were carried out to convert the optically pure compound (–)-**16** into the previously described^[8] (+)-1,3-diacetoxy-5-hydroxycyclohexane **22** (Scheme 4). Inversion of the free hydroxyl group in **16** under Mitsunobu conditions furnished **21**. Subsequent removal of the silyl ether with TBAF afforded the corresponding diacetylated diol (+)-**22**. The comparison of the specific rotation of this compound to that described in the literature led us to determine the (1*R*,3*S*,5*S*)-absolute configuration for the product (–)-**16** obtained from the enzymatic acylation.^[8]

The synthesis of the A-ring synthon was completed with three additional steps (Scheme 3). The treatment of **16** with TBDMSCl and imidazole led us to achieve the compound **17**, which bears orthogonal protection for its three hydroxyl groups. Sequentially, the removal of acetyl group in basic conditions afforded the alcohol **18**, which was treated with Dess-Martin

periodinane reagent to give the final A-ring synthon **19**. The absolute configuration was maintained in all steps, as it was verified by chiral HPLC analysis of compound **18** (see Figure S4, Supporting Information).



Scheme 5. Synthesis of 19-*nor*-vitamin D analogues. Reaction conditions: (a) LHMDS, THF, -78°C to -50°C , 7 h (63%); (b) $\text{Bi}(\text{OTf})_3$, CH_2Cl_2 , 0°C , 2 h (75%); (c) EtOH sat HCl, r.t., 30 min (89%).

A-Ring modified 19-*nor*-vitamin D₃ analogues were synthesized through the Julia-modified coupling reaction as illustrated in Scheme 5. Reaction of ketone **19** with the lithium enolate of sulfone **12** gave a mixture of diastereomers **23** and **24**. The separation of **23** and **24** by semipreparative HPLC was not

possible due to their low polarity, which was later modulated through hydroxyl group deprotection.

On the other hand, the hydroxyl groups must be differentiated from each other for stereochemical determination. Therefore, different conditions were tested to carry out the selective deprotection of TBDMS vs TBDPS group. The best result was achieved using a Lewis acid, $\text{Bi}(\text{OTf})_3$, in an organic solvent. The removal of the ethoxymethyl protecting group in the side chain took place simultaneously, providing a 1.37:1 diastereomeric mixture of analogues **25** and **26** that were successfully separated by HPLC. At this stage, we called diastereomer compounds A and B according to the rate of elution in the HPLC chromatogram (see Figure S5, Supporting Information). The identification of the synthesized analogues was performed by NMR. The protons at C6 and C7 in the ^1H NMR spectrum, and also the signals corresponding to the carbons C14 and C17 could be identified by monodimensional DEPT-135, DEPT-90 and bidimensional ^{13}C - ^1H HMBC analysis (see pp S55-S60, Supporting Information). At this point, the 1D NMR selective NOE experiments were the key to undoubtedly complete the structure elucidation for both isomers. In the case of compound A, the selective irradiation of H7 allowed us to identify H10 (Figure 3). This signal was also showed in the 1D NMR selective NOE experiment on the multiplet at 4.08 ppm. In this second experiment we could also observe NOE signals with the *ortho* aromatic protons of the TBDPS group. This proved that the signal at 4.08 ppm belonged to the proton adjacent to OTBDPS and that this silyl ether was in the position C1. Moreover, this aromatic signal and H7 were close enough to exhibit a NOE enhancement. These data led us to identify the isomer A with the structure of **25**. This assignment could be verified analyzing the selective NOE experiment on H3 and H6, where we were able to observe the signals of H4.




Figure 3. Selective 1D NOE experiments on compound A.




Figure 4. Selective 1D NOE experiments on compound B.

The same argument could be applied for the structure elucidation of compound B (Figure 4). The *ortho* aromatic protons exhibited NOE enhancement with H6, which in turn transferred nuclear spin polarization through transverse relaxation with H4. This effect was also observed between H4 and the proton in alpha position to OTBDPS group. These data ratified the assignment of compound B with the structure of **26**. In this case, the anisotropy effect of the aromatic ring made possible to observe the *ortho* protons when H6 was irradiated.

After successfully complete structure elucidation of the isomers **25** and **26**, the TBDPS group was removed with a saturated solution of HCl in EtOH, giving the final compounds **7** and **8**, respectively.

Biological Evaluation

The biological activity of the newly synthesized analogues was tested *in vitro*, and the results are summarized in Table 2 and Figures 5-8.

Table 2. Biological activities of 19-*nor* analogues of $1\alpha,25-(\text{OH})_2\text{-D}_3$.^{a)}

Compound	VDR (%)	hDBP (%)	MFC-7 (%)	HL 60 (%)
$1\alpha,25-(\text{OH})_2\text{-D}_3$	100	100	100	100
19- <i>nor</i> - $1\alpha,25-(\text{OH})_2\text{-D}_3$	100	10	116	170
7	1.2	14	18	10
8	0.4	3	12	6

^{a)} Values are expressed as percentages of activity EC_{50} concentration relative to $1\alpha,25-(\text{OH})_2\text{-D}_3$ (100%).

The affinity of compounds **7** and **8** for pig mucosa cytosol VDR and for human vitamin D binding protein (hDBP) was evaluated in comparison to the natural hormone and its 19-*nor* derivative. In addition, inhibition of MCF-7 breast cancer and HL60

leukemia cell proliferation by $1\alpha,25-(\text{OH})_2\text{-D}_3$, $1\alpha,25-(\text{OH})_2\text{-19-nor-D}_3$, and analogues **7** and **8** was measured.




Figure 5. Affinity of $1\alpha,25-(\text{OH})_2\text{-D}_3$ and 19-*nor* analogues for pig vitamin D receptor (VDR). Notes: $1\alpha,25-(\text{OH})_2\text{-D}_3$ (●); $1\alpha,25-(\text{OH})_2\text{-19-nor-D}_3$ (■); **7** (▼); **8** (□).

The $1\alpha,25-(\text{OH})_2\text{-19-nor-D}_3$ analogue, possessing the same configuration of the natural hormone at C-1 and C-3 positions, has the same potency in terms of its ability to bind to the pig VDR, but analogues **7** and **8** have markedly reduced affinity for the VDR (Table 2 and Figure 5).

When comparing hDBP binding among the three 1,25-19-*nor* analogues, compound **7** exhibited the highest affinity, which was still seven times lower than that of $1\alpha,25-(\text{OH})_2\text{-D}_3$ (Table 2 and Figure 6).




Figure 6. Affinity of $1\alpha,25-(\text{OH})_2\text{-D}_3$ and 19-nor analogues for human vitamin D binding protein (hDBP). Notes: $1\alpha,25-(\text{OH})_2\text{-D}_3$ (●); $1\alpha,25-(\text{OH})_2\text{-19-nor-D}_3$ (■); 7 (▼); 8 (□).

As a measure of the antiproliferative activity of $1,25\text{-19-nor}$ analogues, $[^3\text{H}]$ thymidine incorporation of MCF-7 breast cancer cells and HL 60 leukemia cells was measured after a 72 h incubation period with various concentrations of $1\alpha,25-(\text{OH})_2\text{-D}_3$, analogues or ethanol. The most active compound is the $1\alpha,25-(\text{OH})_2\text{-19-nor-D}_3$, which is slightly more active than the natural hormone. Analogues 7 and 8 showed 6-10 and 8-17 fold lower activities than $1\alpha,25$, respectively, on MCF-7 and HL 60 cells (Table 1 and Figures 7 and 8).




Figure 7. In vitro antiproliferative effects of $1\alpha,25-(\text{OH})_2\text{-D}_3$ and 19-nor analogues on breast cancer MCF-7 cells. Notes: Vehicle (○); $1\alpha,25-(\text{OH})_2\text{-D}_3$ (●); $1\alpha,25-(\text{OH})_2\text{-19-nor-D}_3$ (■); 7 (▼); 8 (□).




Figure 8. In vitro antiproliferative effects of $1\alpha,25-(\text{OH})_2\text{-D}_3$ and 19-nor analogues on promyelocytic HL 60 leukemia cells. Notes: Vehicle (○); $1\alpha,25-(\text{OH})_2\text{-D}_3$ (●); $1\alpha,25-(\text{OH})_2\text{-19-nor-D}_3$ (■); 7 (▼); 8 (□).

These findings prove the key role of the stereochemistry in the biological activity and this would be reflected in different pharmacokinetic profiles of these analogues.

Conclusion

The synthesis of A-ring diastereomers of $1\alpha,25-(\text{OH})_2\text{-19-nor-D}_3$ has been successfully accomplished. For the construction of the diene unit, a strategy based on a Julia-Kocienski olefination between the sulfone **12** and the cyclohexanone derivative **11** was employed. *cis,cis*-1,3,5-Cyclohexanetriol, a commercial available compound with the appropriate stereochemistry, was used as starting material for the A-ring precursor. To elucidate the structure of the 19-nor analogues, an alternative synthesis was carried out through orthogonally protected derivatives. It is noteworthy the importance of the biocatalytic desymmetrization process of **15** to give different chemical nature to the A-ring hydroxyl groups. This step was successfully performed with *Pseudomonas cepacia* lipase as catalyst, vinyl acetate as acylating reagent, and toluene or TBME as solvents. The preparation of these 19-nor analogues has not been described previously, probably due to the complexity in structure elucidation of the diastereoisomers. The structure of both compounds was established by selective NOE NMR spectroscopy, homonuclear (COSY, TOCSY) and heteronuclear (HSQC, HMBC) correlations. Biological assays on $1,25\text{-19-nor}$ analogues 7 and 8 have shown poor binding to VDR, whereas $1\alpha,25-(\text{OH})_2\text{-19-nor-D}_3$ has the same affinity as the natural hormone. All three $1,25\text{-19-nor}$ analogues have a lower affinity for hDBP than $1\alpha,25-(\text{OH})_2\text{-D}_3$. The most active compound in the inhibition of MCF-7 cell proliferation and HL 60 cell

differentiation was $1\alpha,25\text{-(OH)}_2\text{-19-nor-D}_3$, even slightly higher than $1\alpha,25$.

Experimental Section

General Considerations. All reagents were at highest commercial quality and used without further purification. All non-aqueous reactions were carried out under argon atmosphere in anhydrous, freshly distilled, solvents. *Candida antarctica* lipase type B (CAL-B, Novozyme 435, immobilized by adsorption in Lewatit, 9120 PLU/g) was kindly donated by Novozyme. *Pseudomonas cepacia* lipase (Lipase PS "Amano IM", immobilized on diatomaceous earth, 943 U/g) was purchased from Amano Enzyme. Reactions were monitored by TLC carried out using UV light as visualizing agent and/or spraying a 5% aqueous sulphuric acid solution containing cerium(IV) sulphate (1%) and molybdophosphoric acid (2.5%). Flash chromatography was performed using silica gel 60 (230–400 mesh). ^1H , ^{13}C NMR, and DEPT were obtained using 300.13, 400.13 or 600.13 MHz apparatus for ^1H , and 75.5, 90.61 or 150.90 MHz for ^{13}C . The same spectrometers were used for the acquisition of ^1H - ^1H homonuclear (COSY, TOCSY, and NOESY) and ^1H - ^{13}C heteronuclear (HSQC and HMBC) correlations. Optical rotations were recorded on a polarimeter, and values are reported as follows: $[\alpha]_D^{25}$ (c: g/100 mL, solvent). IR spectra were recorded as thin films on NaCl plates or KBr pellets on an Infrared FT spectrophotometer. Mass spectra (MS) and high resolution mass spectra (HRMS) were recorded on a mass spectrometer under electron spray ionization (ESI) or atmospheric pressure chemical ionization (APCI) conditions.

$1\alpha,25$ -Dihydroxy-3-*epi*-19-*nor*-vitamin D_3 (7**).** To a solution of **13** (13.86 mg, 0.03 mmol) or **25** (19.29 mg, 0.03 mmol) in EtOH (622 μL), a saturated solution of HCl in EtOH (7.6 mL) was added. The reaction was stirred for 30 min. Then, the solvent was removed, the mixture was extracted with a saturated aqueous solution of NaHCO_3 and Et_2O , and the organic extract was washed with brine and dried (Na_2SO_4). The residue was purified by column chromatography using 80% EtOAc/hexane as eluent. Rf: 0.2 (90% EtOAc/hexane); ^1H NMR (600.13 MHz, CDCl_3): δ 0.54 (s, 3H, Me_{18}), 0.84 (m, 1H), 0.93 (d, 3H, Me_{21} , J 6.4 Hz), 1.21 (s, 6H, $\text{Me}_{26} + \text{Me}_{27}$), 1.25–2.10 (several m), 2.25 (dd, 1H, $\text{H}_{4\text{ax}}$, J 13.2, 7.1 Hz), 2.40 (d, 1H, $\text{H}_{10\text{ax}}$, J 13.1, 7.1 Hz), 2.48 (dd, 1H, $\text{H}_{4\text{eq}}$, J 13.7, 3.6 Hz), 2.59 (dd, 1H, $\text{H}_{10\text{eq}}$, J 13.5, 3.5 Hz), 2.81 (dd, 1H, $\text{H}_{9\text{eq}}$, J 12.4, 4.0 Hz), 3.90 (m, 1H, $\text{H}_1 + \text{H}_3$), 5.85 (d, 1H, H_7 , J 11.2 Hz), 6.31 (d, 1H, H_6 , J 11.3 Hz) ppm; ^{13}C NMR (150.5 MHz, CDCl_3): δ 12.2 (Me_{18}), 19.0 (Me_{21}), 21.0 (CH_2), 22.4 (CH_2), 23.6 (CH_2), 27.8 (CH_2), 29.0 (CH_2), 29.3 and 29.5 ($\text{Me}_{26} + \text{Me}_{27}$), 36.2 (CH, C_{20}), 36.5 (CH_2), 37.0 (CH_2), 40.6 (CH, C_2), 41.4 (CH_2), 44.6 (CH_2), 45.3 (CH_2), 45.9 (C, C_{13}), 56.5 and 56.7 (2CH, C_{14} and C_{17}), 68.7 and 69.0 (2CH, C_1 and C_3), 71.3 (C, C_{25}), 115.6 (CH, C_7), 124.2 (CH, C_6), 130.1, and 142.9 (2CH, $\text{C}_5 + \text{C}_8$) ppm; MS (ESI $^+$, m/z): 405 [(M+H) $^+$, 100%].

$1\beta,25$ -Dihydroxy-19-*nor*-vitamin D_3 (8**).** For the synthesis of this derivative, we employed the same procedure as **7** but starting from **14** or **26**. Rf: 0.2 (90% EtOAc/hexane); ^1H NMR (600.13 MHz, CDCl_3): δ 0.55 (s, 3H, Me_{18}), 0.88 (m, 1H), 0.93 (d, 3H, Me_{21} , J 6.5 Hz), 1.21 (s, 6H, $\text{Me}_{26} + \text{Me}_{27}$), 1.25–2.07 (several m), 2.30 (dd, 1H, $\text{H}_{4\text{ax}}$, J 13.4, 6.0 Hz), 2.47 (apparent d, 2H, $\text{H}_{4\text{eq}} + \text{H}_{10\text{eq}}$, J 13.6 Hz), 2.56 (dd, 1H, $\text{H}_{10\text{ax}}$, J 13.7, 6.1 Hz), 2.81 (dd, 1H, $\text{H}_{9\text{eq}}$, J 11.7, 4.1 Hz), 4.00 (m, 2H, $\text{H}_1 + \text{H}_3$), 5.86 (d, 1H, H_7 , J 11.2 Hz), 6.34 (d, 1H, H_6 , J 11.2 Hz) ppm; ^{13}C NMR (150.5 MHz, CDCl_3): δ 12.2 (Me_{18}), 19.0 (Me_{21}), 21.0 (CH_2), 22.4 (CH_2), 23.6 (CH_2), 27.8 (CH_2), 29.1 (CH_2), 29.4 and 29.5 ($\text{Me}_{26} + \text{Me}_{27}$), 36.3 (CH, C_{20}), 36.5 (CH_2), 36.8 (CH_2), 40.4 (CH, C_2), 41.0 (CH_2), 44.6 (CH_2), 44.8 (CH_2), 45.9 (C, C_{13}), 56.4 and 56.6 (2CH, C_{14} and C_{17}), 68.8 and 69.0 (2CH, C_1 and C_3), 71.3 (C, C_{25}), 115.5 (CH, C_7),

124.2 (CH, C_6), 130.1 and 142.9 (2CH, $\text{C}_5 + \text{C}_8$) ppm; MS (ESI $^+$, m/z): 405 [(M+H) $^+$, 100%].

(1*r*,3*R*,5*S*)-3,5-bis(*tert*-Butyldimethylsilyloxy)cyclohexanol (10**).** To a solution of **9** (1.0 g, 7.57 mmol) in anhydrous THF (30 mL) at -20 $^\circ\text{C}$, were successively added anhydrous Et_3N (2.1 mL, 15.14 mmol) and *tert*-butyldimethylsilyl chloride (2.3 g, 15.14 mmol). The reaction was stirred at this temperature for 2 h and then 16 h at r.t. The solvent was evaporated and the crude was purified by column chromatography (30% Et_2O /hexane) to give the compound **10** as a white solid in 43% yield; Rf: 0.4 (30% Et_2O /hexane); mp 78–80 $^\circ\text{C}$; IR (KBr): ν 3269, 2943, 2928, 1471, 1463, 1378 cm^{-1} ; ^1H NMR (300.13 MHz, CDCl_3): δ 0.05 (s, 12H, SiMe), 0.87 (s, 18H, SiCMe_3), 1.32 (m, 3H, $\text{H}_{2\text{ax}} + \text{H}_{4\text{ax}} + \text{H}_{6\text{ax}}$), 1.72 (s, 2H, OH), 1.99 (m, 1H, $\text{H}_{6\text{eq}}$), 2.11 (m, 2H, $\text{H}_{2\text{eq}} + \text{H}_{4\text{eq}}$), 3.57 (m, 3H, $\text{H}_1 + \text{H}_3 + \text{H}_5$) ppm; ^{13}C NMR (75.5 MHz, CDCl_3): δ -4.6 (SiMe), -4.5 (SiMe), 18.3 (SiC), 26.0 (CH_3 , SiCMe_3), 44.8 ($\text{C}_2 + \text{C}_6$), 45.1 (C_4), 66.2 (C_1), 66.7 ($\text{C}_3 + \text{C}_5$) ppm; MS (APCI $^+$, m/z): 361 [(M+H) $^+$, 25%], 383 [(M+Na) $^+$, 100%].

(3*R*,5*S*)-3,5-bis(*tert*-Butyldimethylsilyloxy)cyclohexanone (11**).** To a solution of **10** (295 mg, 0.82 mmol) in anhydrous CH_2Cl_2 (8.2 mL), Dess-Martin reagent was added (381 mg, 0.898 mmol). The mixture was stirred at r.t. for 30 min. Then, it was diluted with Et_2O (9.5 mL) and a mixture of saturated aqueous $\text{Na}_2\text{S}_2\text{O}_3$ and NaHCO_3 solution (1:1, v/v, 9.5 mL), obtaining a white precipitate that disappeared after 10 min. The mixture was extracted with Et_2O . The combined organic fractions were dried (Na_2SO_4), filtered and concentrated. Purification of the crude by column chromatography (5% Et_2O /hexane) gave **11** as a white solid in 97% yield; Rf: 0.4 (10% Et_2O /hexane); mp: 62–64 $^\circ\text{C}$; IR (KBr): ν 2953, 2928, 2856, 1712, 1471, 1463, 1389 cm^{-1} ; ^1H NMR (300.13 MHz, CDCl_3): δ -0.04 (s, 6H, SiMe), 0.04 (s, 6H, SiMe), 0.86 (s, 18H, SiCMe_3), 1.76 (m, 1H, $\text{H}_{4\text{ax}}$), 2.25 (m, 1H, $\text{H}_{4\text{eq}}$), 2.23 (dd, 2H, $\text{H}_{2\text{ax}} + \text{H}_{6\text{ax}}$, J 13.7, 11.2 Hz), 2.53 (dd, 2H, J 13.7, 3.9 Hz, $\text{H}_{2\text{eq}} + \text{H}_{6\text{eq}}$), 3.78 (m, 2H, $\text{H}_3 + \text{H}_5$) ppm; ^{13}C NMR (75.5 MHz, CDCl_3): δ -4.6 (SiMe), 18.1 (SiC), 25.9 (CH_3 , SiCMe_3), 45.2 (C_4), 51.0 ($\text{C}_2 + \text{C}_6$), 66.0 ($\text{C}_3 + \text{C}_5$), 207 (C=O) ppm; MS (ESI $^+$, m/z): 359 [(M+H) $^+$, 5%], 383 [(M+Na) $^+$, 100%].

Procedure for the synthesis of **13 and **14**.** To a solution of **12** (167 mg, 0.30 mmol) in anhydrous THF (1.1 mL) at -78 $^\circ\text{C}$ was added dropwise LHMDS (305 μL , 1.0 M in THF, 0.30 mmol), resulting in a deep red colour solution. The mixture was stirred at the same temperature for 2 h, and then, a solution of the corresponding ketone **11** (63 mg, 0.19 mmol) in anhydrous THF (1.2 mL) was added dropwise to the mixture via cannula transfer. After being stirred at -50 $^\circ\text{C}$ during 5 h, the reaction mixture was poured into a saturated aqueous solution of NH_4Cl and extracted with Et_2O . The combined organic fractions were dried (Na_2SO_4), filtered, and concentrated to give a crude that was purified by column chromatography (4% Et_2O /hexane) to give an equimolar diastereomeric mixture in 51% yield. Then, TBAF (725 μL , 1 M in THF, 0.70 mmol) was added dropwise to the epimeric mixture (100 mg, 0.10 mmol) in anhydrous THF (1.5 mL) at 0 $^\circ\text{C}$ in darkness. After 5 min, the mixture was stirred at r.t. for 2 h. Then, solvent was evaporated and the mixture was extracted with EtOAc. The combined organic fractions were dried (Na_2SO_4), concentrated, and the residue purified by column chromatography (60% Et_2O /hexane). The diastereoisomers were isolated by preparative HPLC (SunFire $^{\text{®}}$ C18 Column, 100 \AA , 5 μm , 10 mm x 250 mm). Conditions: 4.0 mL/min, 10% PrOH /hexane.

25-Ethoxymethoxy-1 α -hydroxy-3-*epi*-19-*nor*-vitamin D_3 (13**).** Rf: 0.2 (60% EtOAc/hexane). IR (NaCl): ν 3367, 2943, 2872, 1463, 1380 cm^{-1} ; ^1H NMR (600.13 MHz, CDCl_3): δ 0.54 (s, 3H, Me_{18}), 0.92 (d, 3H, Me_{21} , J 6.5 Hz), 1.02 (m, 1H, H_{22}), 1.20 (t, 3H, H_3 , J 4.0 Hz), 1.21 (s, 6H, $\text{Me}_{26} + \text{Me}_{27}$), 1.28 (m, 4H, $\text{H}_{17} + \text{H}_{12} + \text{H}_{16}$), 1.39 (m, 5H, $\text{H}_{20} + \text{H}_{22} + \text{H}_{24} + \text{H}_{23}$), 1.51 (m, 6H, $\text{H}_{15} + \text{H}_{24} + \text{H}_3$), 1.66 (m, 3H, $\text{H}_9 + \text{H}_{11}$), 1.78 (m, 1H, $\text{H}_{2\text{ax}}$), 1.88 (m, 1H),

1.99 (dd, 3H, H_{12} , J 11.4, 8.1 Hz), 2.06 (dt, 1H, H_{2eq} , J 12.9, 3.3 Hz), 2.24 (dd, 2H, $H_{4ax} + OH$, 13.2, 7.1 Hz), 2.39 (dd, 1H, H_{10ax} , 13.5, 7.2 Hz), 2.48 (dd, 1H, H_{4ax} , J 14.0, 3.2 Hz), 2.48 (dd, 1H, H_{4eq} , J 13.3, 3.6 Hz), 2.59 (dd, 1H, H_{10eq} , J 13.5, 3.5 Hz), 2.80 (m, 1H, H_9), 3.61 (q, 2H, J 7.1 Hz, H_2), 3.90 (m, 2H, $H_3 + H_1$), 4.75 (s, 2H, H_1), 5.85 (d, 1H, H_7 , J 11.3 Hz), 6.31 (d, 1H, H_6 , J 11.2 Hz) ppm; ^{13}C NMR (150.5 MHz, $CDCl_3$): δ 12.2 (Me_{18}), 15.3 (Me_3), 18.9 (Me_{21}), 20.7 (CH_2 , C_{23}), 22.4 (CH_2 , C_{15}), 23.6 (CH_2 , C_{11}), 26.5 y 26.6 ($Me_{26} + Me_{27}$) 27.8 (CH_2 , C_{16}), 29.0 (CH_2 , C_9), 36.3 (CH , C_{20}), 36.6 (CH_2 , C_{22}), 37.0 (CH_2 , C_{10}), 40.6 (CH_2 , C_{12}), 41.4 (CH_2 , C_2), 42.4 (CH_2 , C_{24}), 45.3 (CH_2 , C_4), 45.9 (C, C_{13}), 56.4 (CH, C_{14}), 56.7 (CH, C_{17}), 63.1 (CH_2 , C_2), 68.7 (CH, C_3), 68.9 (CH, C_1), 76.4 (C, C_{25}), 89.6 (CH_2 , C_1), 115.5 (CH, C_7), 123.8 (CH, C_6), 130.3 (C, C_5), 142.9 (C, C_8) ppm; MS (ESI^+ , m/z): 485 [(M+Na) $^+$, 50%].

25-Ethoxymethoxy-1 β -hydroxy-19-nor-vitamin D₃ (14). Rf: 0.2 (60% EtOAc/hexane). IR (NaCl): ν 3368, 2943, 2872, 1458, 1348 cm^{-1} ; 1H NMR (600.13 MHz, $CDCl_3$): δ 0.54 (s, 3H, Me_{18}), 0.93 (d, 3H, Me_{21} , J 6.5 Hz), 1.03 (dd, 1H, H_{22} , J 20.0, 9.7 Hz), 1.20 (t, 3H, H_3 , J 4.0 Hz), 1.21 (s, 6H, $Me_{26} + Me_{27}$), 1.29 (m, 4H, $H_{17} + 2H_{12} + H_{16}$), 1.40 (m, 4H, $H_{20} + 1H_{22} + 1H_{24} + 1H_{23}$), 1.50 (m, 5H, $H_{15} + 1H_{24} + 2H$), 1.66 (m, 3H, $1H_9 + 2H_{11}$), 1.86 (m, 2H, $1H_2 + 1H_{16}$), 1.99 (m, 3H, $H_2 + H_{14}$), 2.29 (dd, 1H, H_4 , J 13.4, 6.2 Hz), 2.34 (s, 1H, OH), 2.47 (dd, 1H, H_{10} , J 14.0, 3.2 Hz), 2.48 (dd, 1H, H_{10} , J 12.6, 2.7 Hz), 2.56 (dd, 1H, H_{10} , J 13.8, 6.1 Hz), 2.81 (dd, 1H, H_9 , J 13.6, 5.3 Hz), 3.61 (q, 2H, J 7.1 Hz, H_2), 4.00 (m, 2H, $H_3 + H_1$), 4.75 (s, 2H, H_1), 5.86 (d, 1H, H_7 , J 11.3 Hz), 6.33 (d, 1H, H_6 , J 11.3 Hz) ppm; ^{13}C NMR (150.5 MHz, $CDCl_3$): δ 12.2 (Me_{18}), 15.3 (Me_3), 18.9 (Me_{21}), 20.6 (CH_2 , C_{23}), 22.4 (CH_2 , C_{15}), 23.7 (CH_2 , C_{11}), 26.5 and 26.6 ($Me_{26} + Me_{27}$) 27.8 (CH_2 , C_{16}), 29.1 (CH_2 , C_9), 36.3 (CH, C_{20}), 36.6 (CH_2 , C_{22}), 36.8 (CH_2 , C_{10}), 40.4 (CH_2 , C_2), 40.6 (CH_2 , C_{12}), 42.4 (CH_2 , C_{24}), 45.2 (CH_2 , C_4), 45.9 (C, C_{13}), 56.4 (CH, C_{14}), 56.7 (CH, C_{17}), 63.1 (CH_2 , C_2), 68.8 (CH, C_3), 69.0 (CH, C_1), 76.4 (C, C_{25}), 89.6 (CH_2 , C_1), 115.5 (CH, C_7), 124.2 (CH, C_6), 130.1 (C, C_5), 142.9 (C, C_8) ppm; MS (ESI^+ , m/z): 387 [(M-OCH₂OEt) $^+$, 100%], 399 [(M-2OH-Et) $^+$, 100%], 463 [(M+H) $^+$, 75%], 485 [(M+Na) $^+$, 50%].

(1R,3S,5s)-5-(tert-Butyldiphenylsilyloxy)cyclohexane-1,3-diol (15). To a solution of **9** (1 g, 7.18 mmol) in anhydrous THF (20 mL) at r.t. were successively added TBDPSCl (2.3 mL, 8.62 mmol) and anhydrous Et₃N (1.2 mL, 8.62 mmol). After being stirred at this temperature for 30 min, NaH was added (60% w/w in mineral oil, 372 mg, 9.35 mmol). When the solution stopped bubbling, the mixture was heated to 45 °C for 48 h. After this time, it was cooled to 0 °C and filtered over Celite®. Solvents were evaporated and the residue purified by column chromatography (EtOAc as eluent) to give the diol **15** in 85% yield. Rf: 0.4 (80% EtOAc/hexane); mp: 94-96 °C; IR (KBr): ν 3324, 3052, 2939, 2860, 1961, 1904, 1826, 1475 cm^{-1} ; 1H NMR (300.13 MHz, $CDCl_3$): δ 1.06 (s, 9H, $SiCMe_3$), 1.30 (m, 1H, H_{2ax}), 1.44 (dt, 2H, $H_{4ax} + H_{6ax}$, J 17.6, 8.8 Hz), 2.09 (m, 3H, $H_{2eq} + H_{4eq} + H_{6eq}$), 2.24 (s, 2H, OH), 3.46 (ddd, 2H, $H_1 + H_3$, J 14.3, 10.2, 3.9 Hz), 3.67 (m, 1H, H_5), 7.40 (m, 6H, $H_{meta} + H_{para}$), 7.68 (dd, 4H, H_{ortho} , J 7.7, 1.6 Hz) ppm; ^{13}C NMR (75.5 MHz, $CDCl_3$): δ 19.2 (SiC), 27.0 (CH_3 , $SiCMe_3$), 43.4 (CH_2 , C_2), 43.6 ($2CH_2$, $C_4 + C_6$), 65.9 ($2CH$, $C_1 + C_3$), 67.5 (CH, C_5), 127.8 (4CH, C_{meta}), 129.8 ($2CH$, C_{para}), 134.0 ($2C$, C_{ipso}), 135.8 (4CH, C_{ortho}) ppm; MS (ESI^+ , m/z): 371 [(M+H) $^+$, 100%]; HRMS (ESI^+ , m/z): calcd for $C_{22}H_{30}NaO_3Si$ [(M+Na) $^+$]: 393.1856, found: 393.1860.

(1R,3S,5S)-3-(tert-Butyldiphenylsilyloxy)-5-hydroxycyclohexyl acetate (16). Enzymatic reactions: A mixture of compound **15** (540 mg, 1.46 mmol), lipase (270 mg) and vinyl acetate (672 μ L, 7.29 mmol) in the anhydrous solvent (0.2 M, 7.3 mL) was shaken at 30 °C and 250 rpm. The progress of the reaction was analyzed by TLC (50% EtOAc/hexane) until the achievement of the complete conversion (4-12 h). Then, the enzyme was removed by filtration and washed with CH_2Cl_2 . The crude residue was purified by column chromatography (20-40%

EtOAc/hexane as gradient eluent) to give **16** in 99% yield. *Racemic derivative (for the HPLC analyses):* To a solution of **15** (100 mg, 0.27 mmol) in anhydrous CH_2Cl_2 (2.7 mL) at 0 °C, Et₃N (63 μ L, 0.46 mmol), DMAP (4 mg, 0.033 mmol) and acetic anhydride (38 μ L, 0.40 mmol, dropwise) were successively added. The reaction was stirred at r.t. for 2 h and then the solvent was evaporated and the residue purified by column chromatography (20-40% EtOAc/hexane as gradient eluent) to give the racemic derivative **16** (65% yield). Rf: 0.5 (40% EtOAc/hexane); IR (NaCl): ν 3425, 3070, 3048, 2953, 2858, 1961, 1902, 1825, 1737, 1472, 1427 cm^{-1} ; $[\alpha]_D^{20} = -12$ (c 1.0, $CHCl_3$); 1H NMR (300.13 MHz, $CDCl_3$): δ 1.05 (s, 9H, $SiCMe_3$), 1.24-1.67 (m, 4H, $H_{2ax} + H_{4ax} + H_{6ax} + OH$), 2.01 (s, 3H, Me , OAc), 2.10 (m, 3H, $H_{2eq} + H_{4eq} + H_{6eq}$), 3.50 (m, 1H, H_5), 3.69 (m, 1H, H_3), 4.56 (m, 1H, H_1), 7.41 (m, 6H, $H_{meta} + H_{para}$), 7.65 (dd, 4H, H_{ortho} , J 7.7, 1.6 Hz) ppm; ^{13}C NMR (75.5 MHz, $CDCl_3$): δ 19.2 (SiC), 21.4 (Me , OAc), 27.0 (CH_3 , $SiCMe_3$), 39.9 (CH_2), 40.0 (CH_2), 43.7 (CH_2), 65.6 (CH, C_5), 67.1 (CH, C_3), 67.9 (CH, C_1), 127.8 (4CH, C_{meta}), 129.9 (2CH, C_{para}), 133.9 (C, C_{ipso}), 134.0 (C, C_{ipso}), 135.9 (4CH, C_{ortho}), 170.5 (C=O) ppm; MS (ESI^+ , m/z): 413 [(M+H) $^+$, 100%]; HRMS (ESI^+ , m/z): calcd for $C_{24}H_{32}NaO_4Si$ [(M+Na) $^+$]: 435.1962, found: 435.1983.

(1R,3R,5S)-3-(tert-Butyldiphenylsilyloxy)-5-(tert-butylidimethylsilyloxy)cyclohexyl acetate (17). To a solution of **16** (500 mg, 1.21 mmol) in anhydrous CH_2Cl_2 (4.8 mL) at 0 °C, were added imidazole (215 mg, 3.15 mmol) and *tert*-butyldimethylsilyl chloride (439 mg, 2.91 mmol). Afterwards, the reaction was stirred at r.t. for 3 h. Then, solvent was evaporated and the residue purified by column chromatography (10% Et₂O/hexane as eluent) to give **17** in 94% yield. Rf: 0.5 (10% EtOAc/hexane); IR (NaCl): ν 3425, 3070, 3048, 2953, 2858, 1961, 1902, 1825, 1737, 1472, 1427 cm^{-1} ; $[\alpha]_D^{20} = \square$ (c 1.0, $CHCl_3$); 1H NMR (300.13 MHz, $CDCl_3$): δ -0.04 (s, 3H, $SiMe$), -0.03 (s, 3H, $SiMe$), 0.85 (s, 9H, $SiCMe_3$, TBDMS), 1.11 (s, 9H, $SiCMe_3$, TBDPS), 1.36 (m, 2H, $H_{2ax} + H_{6ax}$), 1.51 (dd, 1H, H_{4ax} , J 21.8, 10.3 Hz), 1.98 (m, 1H, H_{4eq}), 2.00 (s, 6H, Me , OAc), 2.09 (m, 1H, H_{2eq}), 2.22 (m, 1H, H_{6eq}), 3.40 (m, 1H, H_3), 3.65 (m, 1H, H_5), 4.57 (m, 2H, H_1), 7.41 (m, 6H, $H_{meta} + H_{para}$), 7.65 (dd, 4H, H_{ortho} , J 7.8, 1.6 Hz) ppm; ^{13}C NMR (75.5 MHz, $CDCl_3$): δ -4.7 ($SiMe$), -4.6 ($SiMe$), 18.1 (SiC), 19.2 (SiC), 21.3 (Me , OAc), 25.9 ($SiCMe_3$, TBDMS), 27.0 ($SiCMe_3$, TBDPS), 40.6 (CH_2 , C_6), 40.9 (CH_2 , C_2), 45.0 (CH_2 , C_4), 66.1 (CH, C_3), 67.2 (CH, C_5), 68.0 (CH, C_1), 127.6 (2CH, C_{meta}), 127.7 (2CH, C_{meta}), 129.8 (2CH, C_{para}), 134.2 (2C, C_{ipso}), 134.4 (2C, C_{ipso}), 135.8 (2CH, C_{ortho}), 135.9 (2CH, C_{ortho}), 170.2 (C=O) ppm; MS (ESI^+ , m/z): 527 [(M+H) $^+$, 100%].

(1R,3R,5S)-3-(tert-Butyldiphenylsilyloxy)-5-(tert-butylidimethylsilyloxy)cyclohexan-1-ol (18). To a solution of **17** (520 mg, 0.99 mmol) in anhydrous MeOH (4.8 mL), MeONa (140 mg, 2.47 mmol) was added, showing a progressive cloudiness. After being stirred at r.t. for 4 h, solid ammonium chloride was added until the medium was neutralized. Then, the solvent was evaporated, the residue was dissolved in EtOAc and it was filtered to remove the salts. The crude was purified by column chromatography (20% Et₂O/hexane as eluent) to give **18** in 95% yield; Rf: 0.4 (20% Et₂O/hexane); IR (NaCl): ν 3349, 3071, 3049, 2951, 2857, 1958, 1887, 1822, 1471, 1427 cm^{-1} ; $[\alpha]_D^{20} = +9$ (c 1.0, $CHCl_3$); 1H NMR (300.13 MHz, $CDCl_3$): δ -0.05 (s, 6H, $SiMe$), 0.84 (s, 9H, $SiCMe_3$, TBDMS), 1.07 (s, 9H, $SiCMe_3$, TBDPS), 1.27 (m, 1H), 1.38 (m, 2H), 1.59 (s, 1H, OH), 1.92 (m, 1H), 2.05 (m, 1H), 2.15 (m, 1H), 3.38 (m, 2H, $H_1 + H_5$), 3.58 (m, 1H, H_3), 7.41 (m, 6H, $H_{meta} + H_{para}$), 7.69 (ddd, 4H, H_{ortho} , J 7.9, 4.5, 1.7 Hz) ppm; ^{13}C NMR (75.5 MHz, $CDCl_3$): δ -4.7 ($SiMe$), -4.6 ($SiMe$), 18.3 (SiC), 19.2 (SiC), 26.0 ($SiCMe_3$, TBDMS), 27.1 ($SiCMe_3$, TBDPS), 44.5 (CH_2), 44.7 (CH_2), 44.8 (CH_2), 66.1 and 66.4 (2CH, $C_1 + C_5$), 67.3 (CH, C_3), 127.7 (4CH, C_{meta}), 129.76 (2CH, C_{para}), 129.81 (CH, C_{para}), 134.31 (C, C_{ipso}), 134.35 (C, C_{ipso}), 135.86 (2CH, C_{ortho}), 135.88 (2CH, C_{ortho}) ppm; MS (ESI^+ , m/z): 485 [(M+H) $^+$, 100%].

(3S,5R)-3-(tert-Butyldiphenylsilyloxy)-5-(tert-butyldimethylsilyloxy)cyclohexanone (19). To a solution of **18** (452 mg, 0.93 mmol) in anhydrous CH₂Cl₂ (9.0 mL), Dess-Martin reagent was added (448 mg, 1.02 mmol). The mixture was stirred at r.t. for 1 h and then, it was diluted with Et₂O (9.5 mL) and a mixture of saturated aqueous Na₂S₂O₃ and NaHCO₃ solution (1:1, v/v, 9.5 mL), obtaining a white precipitate that disappeared after 10 min. After that, the mixture was extracted with Et₂O. The combined organic fractions were dried (Na₂SO₄), filtered and concentrated. Purification of the crude by column chromatography (10% Et₂O/hexane) gave **19** in 97% yield; Rf: 0.7 (20% Et₂O/hexane); IR (KBr): ν 3064, 3049, 2951, 2890, 1958, 1894, 1822, 1717, 1467, 1427 cm⁻¹; [α]_D²⁰ = -1 (c 1.0, CHCl₃); ¹H NMR (300.13 MHz, CDCl₃): δ -0.03 (s, 6H, SiMe), 0.86 (s, 9H, SiCMe₃, TBDMS) 1.11 (s, 9H, SiCMe₃, TBDPS), 1.84 (m, 1H, H_{4ax}), 2.17 (m, 1H, H_{4eq}), 2.35 (dd, 1H, H_{6ax}), 13.8, 11.1 Hz), 2.50 (dt, 2H, H_{2ax} + H_{6eq}, J 14.0, 7.0 Hz), 2.63 (dd, 1H, H_{2eq}, J 14.1, 5.1 Hz), 3.59 (m, 1H, H₅), 3.84 (m, 1H, H₃), 7.42 (m, 6H, H_{meta} + H_{para}) and 7.70 (ddd, 4H, H_{ortho}, J 16.8, 7.6, 1.5 Hz) ppm; ¹³C NMR (75.5 MHz, CDCl₃): δ -4.9 (SiMe), -4.8 (SiMe), 18.1 (CSi), 19.1 (SiC), 25.8 (SiCMe₃, TBDMS), 27.0 (SiCMe₃, TBDPS), 44.7 (CH₂, C₄), 50.6 (CH₂, C₂), 50.9 (CH₂, C₆), 65.6 (CH, C₅), 66.6 (CH, C₃), 127.8 (4CH, C_{meta}), 130.0 (2CH, C_{para}), 133.5 (C, C_{ipso}), 133.8 (C, C_{ipso}), 135.7 (2CH, C_{ortho}), 135.8 (2CH, C_{ortho}), 207.1 (C=O) ppm; MS (ESI⁺, m/z): 483 [(M+H)⁺, 100%].

(1R,3S,5s)-5-(tert-Butyldiphenylsilyloxy)cyclohexan-1,3-diyl diacetate (20). By-product of the enzymatic reaction. Rf: 0.8 (40% EtOAc/hexane); IR (NaCl): ν 3071, 3049, 2954, 2930, 2857, 1959, 1887, 1738, 1471, 1427 cm⁻¹; ¹H NMR (300.13 MHz, CDCl₃): δ 1.05 (s, 9H, SiCMe₃), 1.34 (q, 1H, H_{2ax}, J 11.6 Hz), 1.48 (c, 2H, H_{4ax} + H_{6ax}, J 11.7 Hz), 2.00 (s, 6H, Me, OAc), 2.19 (m, 3H, H_{2eq} + H_{4eq} + H_{6eq}), 3.67 (m, 1H, H₅), 4.53 (m, 2H, H₁ + H₃), 7.41 (m, 6H, H_{meta} + H_{para}), 7.65 (dd, 4H, H_{ortho}, J 7.8, 1.6 Hz) ppm; ¹³C NMR (75.5 MHz, CDCl₃): δ 19.2 (SiC), 21.2 (Me, OAc), 27.0 (CH₃, Me₂CSi), 36.5 (CH₂, C₂), 40.5 (CH₂, C₄ + C₆), 66.7 (CH, C₅), 67.3 (CH, C₁ + C₃), 127.8 (4CH, C_{meta}), 129.9 (2CH, C_{para}), 133.8 (2C, C_{ipso}), 135.8 (4CH, C_{ortho}), 170.1 (C=O) ppm; MS (ESI⁺, m/z): 455 [(M+H)⁺, 100%].

(1R,3R)-5-(tert-Butyldiphenylsilyloxy)cyclohexan-1,3-diyl diacetate (21). To a solution of (-)-**16** (60 mg, 0.15 mmol) in anhydrous THF (250 μL), were successively added PPh₃ (57 mg, 0.22 mmol), DIAD (42 μL, 0.22 mmol, dropwise) and acetic acid (13 μL, 0.22 mmol, dropwise). After being stirred at r.t. for 4 h, the solvent was evaporated, and the residue purified by column chromatography (20% Et₂O/hexane) to give the diacetate **21** (72%). Rf: 0.2 (20% Et₂O/hexane); IR (NaCl): ν 3071, 3049, 2958, 2857, 1961, 1892, 1741, 1734, 1471, 1427 cm⁻¹; [α]_D²⁰ = +1 (c 1.0, CHCl₃); ¹H NMR (300.13 MHz, CDCl₃): δ 1.05 (s, 9H, SiCMe₃), 1.50 (m, 3H, H_{2ax} + H_{4ax} + H_{6ax}), 1.80 (s, 3H, Me, OAc), 1.86 (m, 1H, H_{4eq}), 1.96 (m, 1H, H_{2eq}), 2.02 (s, 3H, MeC=O), 2.26 (m, 1H, H_{4eq}), 3.90 (m, 1H, H₅), 4.88 (m, 1H, H₃), 5.14 (m, 1H, H₁) 7.39 (m, 6H, H_{meta} + H_{para}), 7.70 (dd, 4H, H_{ortho}, J 7.7, 1.6 Hz) ppm; ¹³C NMR (75.5 MHz, CDCl₃): δ 19.2 (SiC), 21.2 (Me, OAc), 21.4 (Me, OAc), 27.0 (SiCMe₃), 34.9 (CH₂, C₂), 38.6 (CH₂, C₆), 40.5 (CH₂, C₄), 66.4 (CH, C₅), 68.0 (CH, C₃), 68.7 (CH, C₁), 127.7 (2CH, C_{meta}), 127.8 (2CH, C_{meta}), 129.82 (CH, C_{para}), 129.83 (CH, C_{para}), 134.0 (C, C_{ipso}), 134.1 (C, C_{ipso}), 135.8 (2CH, C_{ortho}), 135.9 (2CH, C_{ortho}), 170.0 (C=O), 170.4 (C=O) ppm; MS (ESI⁺, m/z): 455 [(M+H)⁺, 100%].

(1S,3S)-5-Hydroxycyclohexan-1,3-diyl diacetate (22). TBAF (219 μL, 0.22 mmol, 1.0 M in THF) was added dropwise to a solution of silyl ether **21** (40 mg, 0.09 mmol) in anhydrous THF (437 μL) at 0 °C in darkness. The reaction was stirred at r.t. until TLC (60% Et₂O/hexane) shows complete consumption of starting material (3 h). Then, solvent was evaporated and the mixture was extracted with EtOAc. The combined organic fractions were dried (Na₂SO₄) and concentrated under vacuum. The

crude was purified by column chromatography (30% EtOAc/hexane) to give **22** in 79% yield. Rf: 0.3 (30% AcOEt/hexane); IR (NaCl): ν 3444, 2958, 2865, 1738, 1734, 1716, 1435, 1372, 1256, 1238 cm⁻¹; [α]_D²⁰ = +13.8 (c 1.0, CHCl₃); ¹H NMR (300.13 MHz, CDCl₃): δ 1.53 (m, 3H, H_{2ax} + H_{4ax} + H_{6ax}), 1.96 (s, 1H, OH), 2.05 (s, 3H, Me, OAc), 2.06 (s, 3H, Me, OAc), 2.08 (m, 2H), 2.28 (m, 1H), 4.03 (m, 1H, H₅), 5.05 and 5.28 (2m, 2H, H₁ + H₃) ppm; ¹³C NMR (75.5 MHz, CDCl₃): δ 21.3 (Me, OAc), 21.4 (Me, OAc), 34.9 (CH₂), 38.3 (CH₂), 40.0 (CH₂), 65.2 (CH, C₅), 68.2 and 68.5 (2CH, C₃ + C₁), 170.3 (C=O), 170.4 (C=O) ppm; MS (ESI⁺, m/z): 217 [(M+H)⁺, 100%].

Procedure for the synthesis of 25 and 26. To a solution of **12** (300 mg, 0.55 mmol) in anhydrous THF (1.8 mL) at -78 °C was added dropwise LHMDS (520 μL, 1.0 M in THF, 0.52 mmol), resulting in a deep red color solution. The mixture was stirred at the same temperature for 2 h and then, a solution of the corresponding ketone **19** (264 mg, 0.55 mmol) in anhydrous THF (1.2 mL) was added dropwise via cannula transfer. After being stirred at -50 °C during 5 h, the reaction was poured into a saturated aqueous solution of NH₄Cl and extracted with Et₂O. The combined organic fractions were dried (Na₂SO₄), filtered, and concentrated to give a crude that was purified by column chromatography (4% Et₂O/hexane). Then, the resulting mixture (269 mg, 0.33 mmol) was dissolved in anhydrous CH₂Cl₂ (3.3 mL), Bi(OTf)₃ (238 mg, 0.36 mmol) was added and the mixture was stirred at 0 °C for 2 h. The reaction was quenched by adding a saturated aqueous solution of NaHCO₃. Next, it was diluted with CH₂Cl₂ and filtered over Celite®. Solvents were evaporated under vacuum and the residue purified by column chromatography (50% Et₂O/hexane). The diastereoisomers were isolated by preparative HPLC (SunFire® C18 Column, 100 Å, 5 μm, 10 mm x 250 mm). Conditions: 5.0 mL/min, 5% iPrOH/hexane.

1α-(tert-Butyldiphenylsilyloxy)-25-hydroxy-3-epi-19-nor-vitamin D₃ (25). Rf: 0.4 (70% Et₂O/hexane); ¹H NMR (600.13 MHz, CDCl₃): δ 0.51 (s, 3H, Me₁₈), 0.88 (m, 1H), 0.94 (d, 3H, Me₂₁, J 6.4 Hz), 1.06 (s, 9H, SiCMe₃), 1.23 (s, 6H, Me₂₆ + Me₂₇), 1.25–2.07 (several m, 19H), 2.19 (d, 1H, H_{10eq}, J 13.8 Hz), 2.37 (dd, 2H, H₄, J 10.2, 4.4 Hz), 2.47 (dd, 1H, H_{10ax}, J 13.7, 5.7 Hz), 2.82 (m, 1H, H₉), 3.16 (d, 1H, J 8.6 Hz), 3.85 (br s, 1H, H₃), 4.08 (br s, 1H, H₁), 5.73 (d, 1H, H₇, J 11.2 Hz), 6.33 (d, 1H, H₆, J 11.3 Hz), 7.38 (q, 4H, H_{meta}, J 7.1 Hz), 7.43 (m, 2H, H_{para}), 7.67 (d, 2H, J 6.6 Hz,), 7.71 (d, 2H, J 7.71 Hz) ppm; ¹³C NMR (150.5 MHz, CDCl₃): δ 12.3 (Me₁₈), 18.9 (Me₂₁), 19.4 (CSi), 21.0 (CH₂), 22.5 (CH₂), 23.6 (CH₂), 27.2 (SiCMe₃), 27.8 (CH₂), 29.0 (CH₂) 29.3 y 29.5 (Me₂₆ + Me₂₇), 36.3 (CH, C₂₀), 36.5 (CH₂), 36.6 (CH₂), 40.7 (CH₂, C₂), 40.5 (CH₂), 44.6 (CH₂), 45.5 (CH₂), 45.9 (C, C₁₃), 56.4 and 56.7 (2CH, C₁₄ + C₁₇), 68.9 (CH, C₃), 70.6 (CH, C₁), 71.5 (C, C₂₅), 115.8 (CH, C₇), 124.0 (CH, C₆), 127.75 and 127.83 (2CH, C_{meta}), 129.90 and 130.02 (2CH, C_{para}), 130.6 (C₅), 133.4 and 133.7 (2C, C_{ipso}) 135.97 and 136.06 (2CH, C_{ortho}), 142.3 (C₈) ppm.

3-(tert-Butyldiphenylsilyl)-1β,25-dihydroxy-19-nor-vitamin D₃ (26). Rf: 0.4 (70% Et₂O/hexane); ¹H NMR (600.13 MHz, CDCl₃): δ 0.53 (s, 3H, Me₁₈), 0.88 (m, 1H), 0.94 (d, 3H, Me₂₁, J 6.4 Hz), 1.05 (s, 9H, SiCMe₃), 1.22 (s, 6H, Me₂₆ + Me₂₇), 1.25–2.07 (several m, 20 H), 2.18 (m, 1H, H_{4eq}), 2.40 (dd, 1H, H_{10eq}, J 13.4, 3.3 Hz), 2.54 (dd, 1H, H_{10ax}, J 13.5, 6.3 Hz), 2.78 (dd, 1H, H_{9eq}, J 14.2, 4.4 Hz), 2.94 (d, 1H, H_{2eq}, J 9.1 Hz), 3.84 (br s, 1H, H₁), 3.99 (m, 1H, H₃), 5.14 (br s, 1H, OH), 5.86 (d, 1H, H₇, J 11.2 Hz), 6.16 (d, 1H, H₆, J 11.2 Hz), 7.38 (m, 4H, H_{meta}), 7.43 (m, 2H, H_{para}), 7.67 (d, 2H, J 7.9 Hz,), 7.70 (d, 2H, J 6.7 Hz) ppm; ¹³C NMR (150.5 MHz, CDCl₃): δ 12.2 (Me₁₈), 18.9 (Me₂₁), 19.2 (CSi), 21.0 (CH₂), 22.4 (CH₂), 23.6 (CH₂), 27.2 (SiCMe₃), 27.9 (CH₂), 29.0 (CH₂), 29.4 and 29.5 (Me₂₆ + Me₂₇), 36.3 (CH, C₂₀), 36.6 (CH₂), 37.1 (CH₂), 40.4 (CH₂), 40.6 (CH₂), 44.5 (CH₂), 45.2 (CH₂), 45.9 (C, C₁₃), 56.4 and 56.6 (2CH, C₁₄ + C₁₇), 68.7 (CH, C₃), 71.0 (CH, C₁), 71.3 (C, C₂₅), 115.9 (CH, C₇), 124.2 (CH, C₆), 127.78 and 127.81 (2CH, C_{meta}), 129.90 and 129.95 (2CH, C_{para}),

130.5 (C₅), 133.7 and 134.0 (2C, C_{ipso}) 136.00 and 136.09 (2CH, C_{ortho}), 142.3 (C₈) ppm.

In vitro Biological Evaluation

Affinity for VDR. The affinity of 1 α ,25-(OH)₂-D₃ and its analogues to the vitamin D receptor was evaluated by their ability to compete with [³H]1 α ,25-(OH)₂-D₃ for binding to high speed supernatant from intestinal mucosa homogenates obtained from normal pigs as described previously.^[12] The relative affinity of the analogues was calculated from their concentration needed to displace 50% of [³H]1 α ,25-(OH)₂-D₃ from its receptor compared with the activity of 1 α ,25-(OH)₂-D₃ (assigned a 100% value).

Affinity for DBP. Binding of vitamin D metabolites and analogues to hDBP was performed at 4 °C as described previously.^[13] [³H]1 α ,25-(OH)₂-D₃ and 1 α ,25-(OH)₂-D₃ or its analogues were incubated with hDBP (0.18 μ M) in a final volume of 1 ml (0.01 M Tris-HCl buffer and 0.154 M NaCl, pH 7.4) for 3 h at 4 °C. Phase separation was then obtained by the addition of 0.5 ml of cold dextran-coated charcoal.

Cell proliferation assays. As a measure of cell proliferation, [³H]-thymidine incorporation of breast cancer MCF-7 cells (ATCC) was determined after a 72 h incubation period with various concentrations of 1 α ,25-(OH)₂-D₃, analogues or vehicle as described previously.^[12]

Cell differentiation assays. Differentiation of promyelocytic HL-60 leukemia cells (ATCC) was measured by the nitro blue tetrazolium (NBT) reduction assay after a 72 h incubation period in the presence of 1 α ,25-(OH)₂-D₃, analogues or vehicle.^[12]

Acknowledgements

Financial support by the Spanish Ministerio de Ciencia e Innovación (MICINN) (Projects CTQ2011-24237 and CTQ2014-55015-P) and Principado de Asturias (Project FC-15-GRUPIN14-002) are gratefully acknowledged. T. G.-G. thanks FICYT (Asturias) for a pre-doctoral fellowship. We also thank Dr. I. Merino (NMR Facility, Universidad de Oviedo) for her assistance in the NMR study.

References

[1] a) D. A. Kennedy, K. Cooley, B. Skidmore, H. Fritz, T. Campbell, D. Seely, *Cancers* **2013**, *5*, 255-280; b) D. Feldman, J. W. Pike, J. S. Adams in *Vitamin D*, Academic Press, New York, **2011**; c) R. Bouillon, W. H. Okamura, A. W. Norman, *Endocr. Rev.* **1995**, *16*, 200-257.
 [2] G.-D. Zhu in *Vitamin D and your body* (Ed.: J. R. Wu-Wong), Bentham eBooks, **2012**.

[3] a) A. W. Norman, R. Bouillon, M. C. Farach-Carson, J. E. Bishop, L.-X. Zhou, I. Nemere, J. Zhao, K. R. Muralidharan, W. H. Okamura, *J. Biol. Chem.* **1993**, *268*, 20022-20030; b) K. R. Muralidharan, A. R. De Lera, S. D. Isaef, A. W. Norman, W. H. Okamura, *J. Org. Chem.* **1993**, *58*, 1895-1899.
 [4] a) S. Yang, C. Smith, H. F. DeLuca, *Biochim. Biophys. Acta* **1993**, *1158*, 279-286; b) K. L. Perlman, R. E. Swenson, H. E. Paaren, H. K. Schnoes, H. F. DeLuca, *Tetrahedron Lett.* **1991**, *32*, 7663-7666; c) K. L. Perlman, R. R. Sicinski, H. K. Schnoes, H. F. DeLuca, *Tetrahedron Lett.* **1990**, *31*, 1823-1824.
 [5] Y. Wu, Y. Zhao, H. Tian, P. DeClercq, M. Vandewalle, M. Berthier, G. Pellegrino, P. Maillos, J.-C. Pascal, *Eur. J. Org. Chem.* **2001**, 3779-3788.
 [6] K. Ono, A. Yoshida, N. Saito, T. Fujishima, S. Honzawa, Y. Suhara, S. Kishimoto, T. Sugiura, K. Waku, H. Takayama, A. Kittaka, *J. Org. Chem.* **2003**, *68*, 7407-7415.
 [7] L. Sánchez-Abella, S. Fernández, A. Verstuyf, L. Verlinden, V. Gotor, M. Ferrero, *J. Med. Chem.* **2009**, *52*, 6158-6162.
 [8] B. Wirz, H. Iding, H. Hilpert, *Tetrahedron: Asymmetry* **2000**, *11*, 4171-4178.
 [9] T. Seitz, K. Harms, U. Koert, *Synthesis* **2014**, *46*, 381-386.
 [10] a) D. Oves, V. Gotor-Fernández, S. Fernández, M. Ferrero, V. Gotor, *Tetrahedron: Asymmetry* **2004**, *15*, 2881-2887; b) S. Fernández, V. Gotor-Fernández, M. Ferrero, V. Gotor, *Curr. Org. Chem.* **2002**, *6*, 453-469; c) M. Díaz, M. Ferrero, S. Fernández, V. Gotor, *Tetrahedron: Asymmetry* **2002**, *13*, 539-546; d) V. Gotor-Fernández, M. Ferrero, S. Fernández, V. Gotor, *J. Org. Chem.* **2002**, *67*, 1266-1270; e) M. Díaz, V. Gotor-Fernández, M. Ferrero, S. Fernández, V. Gotor, *J. Org. Chem.* **2001**, *66*, 4227-4232; f) V. Gotor-Fernández, M. Ferrero, S. Fernández, V. Gotor, *J. Org. Chem.* **1999**, *64*, 7504-7510; g) M. Ferrero, S. Fernández, V. Gotor, *J. Org. Chem.* **1997**, *62*, 4358-4363; h) S. Fernández, M. Ferrero, V. Gotor, W. H. Okamura, *J. Org. Chem.* **1995**, *60*, 6057-6061.
 [11] a) A. Koskinen, A. Klivanov in *Organic Synthesis with Enzymes in Non-Aqueous Media*, Springer Netherlands, **2012**; b) N. G. Munishwar, R. Ipsita, *Eur. J. Biochem.* **2004**, *271*, 2575-2583.
 [12] A. Verstuyf, L. Verlinden, H. Van Baelen, K. Sabbe, C. D'Halleweyn, P. De Clercq, M. Vandewalle, R. Bouillon, *J. Bone Miner. Res.* **1998**, *13*, 549-558.
 [13] R. Bouillon, H. Van Baelen, P. De Moor, *J. Steroid Biochem.* **1980**, *13*, 1029-1034.

UPDATE

Enzymatic Desymmetrization of 19-*nor*-Vitamin D₃ A-Ring Synthon Precursor: Synthesis, Structure Elucidation, and Biological Activity of 1 α ,25-Dihydroxy-3-*epi*-19-*nor*-vitamin D₃ and 1 β ,25-Dihydroxy-19-*nor*-vitamin D₃

Adv. Synth. Catal. **2018**, 360, 000 – 000

Tania González-García, Annemieke Verstuyf, Lieve Verlinden, Susana Fernández,* and Miguel Ferrero*

